Market Overview

Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, and easily one of the most significant. Its novel mechanism offers potent efficacy and yields a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch-tracking series will examine how the perception and performance of Ocrevus evolves through Year One in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera, and a field that perennially debates the merits of early, aggressive intervention.

Questions Answered

  • What is the awareness of, familiarity with, and perceptions related to Ocrevus among U.S. neurologists?
  • For which relapsing MS patients are neurologists prescribing Ocrevus, what are the reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What promotional messages and activities are Genentech/Roche employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare to other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product Description

Emerging Therapies: is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Markets covered: United States

Primary research: Survey of approximately 75 U.S. neurologists

Key metrics included:

  • Unaided and aided awareness of Ocrevus.
  • Familiarity with and impressions of Ocrevus.
  • Prescriber and nonprescriber profiles.
  • Willingness to prescribe Ocrevus.
  • Performance of Ocrevus on key attributes.
  • Sales representative frequency, reach, and satisfaction.
  • Benchmarking against previously launched multiple sclerosis agents.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Ocrevus Relapsing Forms Of Multiple Sclerosis - Wave 3 (US)
    • Key Findings
      • Benchmarking Ocrevus's Launch Success vs. Other Launched Drugs
        • Ocrevus Has Outperformed Most Benchmark DMTs After One Year
      • Prescriber and Nonprescriber Profiles
        • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
        • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Awareness and Perceptions
        • Unaided and Aided Awareness of Ocrevus
          • Ocrevus Is a Top-of-Mind DMT for Surveyed Neurologists at Twelve Months Postlaunch, and Awareness of Its Characteristics Is High
          • Unaided Awareness of Products Approved or Launched for the Treatment of MS
          • Aided Awareness of Ocrevus
          • Aided Awareness of the Comparator Used in Ocrevus's Pivotal Clinical Trials in Relapsing Forms of MS
          • Aided Awareness of Ocrevus's Indication
          • Aided Awareness of Ocrevus's Mechanism of Action and Route of Delivery
          • Aided Awareness of Ocrevus's Dosing Interval
          • Aided Awareness of Ocrevus's Clinical Profile
        • Familiarity with Ocrevus
          • Neurologists' Familiarity with Ocrevus Improved Steadily Across Waves Through Year One
          • Level of Familiarity with Ocrevus
        • Sources of Familiarity with Ocrevus
          • During Ocrevus's First Year, Neurologists' Sources of Familiarity Have Shifted Toward Marketing Contact
        • Initial Reaction to and Interest in Ocrevus
          • Neurologist Reaction to and Interest in Ocrevus Remains Strong After Twelve Months on the Market
          • Ocrevus's Product Profile in Relapsing Forms of MS
          • Ocrevus Information Requiring Additional Information
          • Initial Reaction to Ocrevus
          • Level of Interest in Learning More About Ocrevus
        • Impressions of Ocrevus
          • Neurologists Cite Efficacy and Dosing Frequency as Ocrevus's Key Advantages
          • Unaided Advantages of Ocrevus
          • Unaided Disadvantages of Ocrevus
          • Statement Agreements About Ocrevus for Relapsing Forms of MS
          • Statement Agreements About Ocrevus for Relapsing Forms of MS: Mean
          • Rating of Ocrevus's Risk-Benefit Balance for Relapsing Forms of MS
        • Prescriber and Nonprescriber Profiles
          • Ocrevus Nonprescribers at One Year Postlaunch Have Smaller Practices, Use Older DMTs, and Are More Risk-Averse Than Prescribers
          • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Trial and Use
        • Willingness to Prescribe Ocrevus
          • Surveyed Neurologists Have Been Highly Willing to Prescribe Ocrevus Since Its Launch
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus for Relapsing Forms of MS
          • Mean Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus
        • Number of Patients Currently Receiving Ocrevus
          • The Majority of Ocrevus-Treated Relapsing MS Patients at One Year Postlaunch Were Switched from a Previous DMT
          • Number of Relapsing MS Patients Prescribed Ocrevus
          • Mean Number of Relapsing MS Patients Prescribed Ocrevus
          • Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Mean Ocrevus Discontinuation Rate in Relapsing Forms of MS
          • Reasons for Discontinuing Ocrevus
          • Current Use of DMTs in RR-MS and Relapsing SP-MS Patients
          • Source of Business for Current Ocrevus-Treated Relapsing MS Patients
          • Source Therapy for Relapsing MS Patients Switched to Ocrevus
          • Number of Prior Therapies for Relapsing MS Patients Prescribed Ocrevus
          • Reasons for Starting/Switching to Ocrevus in Relapsing Forms of MS
          • Relapsing Forms of MS Patient Inquiries About Ocrevus
          • Mean Number of Relapsing MS Patients Inquiring About Ocrevus
          • Percentage of Relapsing MS Patients Starting on Ocrevus Following a Request
          • Ocrevus Follow-Up Visits in Relapsing Forms of MS
          • Ocrevus Treatment Response in Relapsing MS
          • Percentage of Relapsing MS Patients Ever Treated with Ocrevus Experiencing Select Adverse Events
        • Reasons for Not Yet Prescribing Ocrevus
          • At Twelve Months Postlaunch, Safety and Market Access Concerns Among Ocrevus Nonprescribers Linger
          • Reasons for Not Prescribing Ocrevus for Relapsing Forms of MS
          • Obstacles to Prescribing Ocrevus for Relapsing Forms of MS
        • Anticipated Ocrevus Use
          • Surveyed Neurologists at Twelve Months Postlaunch Anticipate Robust Growth in Their Prescribing of Ocrevus for Relapsing Forms of MS
          • Anticipated Timing for Ocrevus Prescribing for Relapsing Forms of MS Among Current Nonprescribers
          • Percentage of Relapsing MS Patients Who Are Ocrevus Candidates by Disease Classification
          • Percentage of Relapsing MS Patients Who Are Ocrevus Candidates by Treatment Situation
          • Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Mean Current and Anticipated DMT Treatment Rate in Relapsing Forms of MS
          • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
          • Current and Anticipated Brand Allocation Among DMT-Treated SP-MS Patients
        • Ocrevus Performance on Key Attributes
          • More Surveyed Neurologists at Twelve Months Postlaunch Are Likely to Prescribe Ocrevus Before Lemtrada, Tysabri, and Gilenya
          • Prescribers' Overall Satisfaction with Ocrevus in Relapsing Forms of MS
          • Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Mean Ratings on Statement Agreements Comparing Ocrevus with Other DMTs in the Context of Relapsing Forms of MS
          • Current Reimbursement Limitations on Ocrevus in the Context of Treating Relapsing Forms of MS
          • Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
          • Mean Ratings of Ocrevus's Performance on Clinical and Nonclinical Attributes in the Context of Treating Relapsing Forms of MS
      • Effectiveness of Face-to-Face Detailing for Ocrevus
        • Ocrevus Sales Representative Frequency and Reach
          • Recent Sales Representative Contact Has Remained Low Over Ocrevus's First Year on the Market
          • Sales Representative Detailing and Reach
        • Satisfaction with Ocrevus Sales Representative
          • Satisfaction with Ocrevus Sales Representative Contact Remains High at Twelve Months Postlaunch
          • Mean Satisfaction with Ocrevus Sales Representative
        • Ocrevus Message Recall
          • Ocrevus's Indication for PP-MS Is a Key Topic for Messaging by Sales Representatives at Twelve Months Postlaunch
          • Unaided Ocrevus Message Recall During Recent Detail
          • Aided Ocrevus Message Recall During Recent Detail
      • Methodology
        • Primary Market Research Methodology
        • U.S. Region of Practice
        • State Region of Practice
        • Patient Allocation by Disease Classification
        • Mean Patient Allocation by Disease Classification
        • Percentage of SP-MS Patients Who Suffer Superimposed Relapses
        • Current DMT Treatment Rate by Disease Classification
        • Years in Practice Postresidency
        • Practice Setting
        • Practice Location
      • Appendix
        • Primary Market Research
          • Reasons for Never Prescribing Ocrevus in Relapsing Forms of MS
        • Abbreviations

    Author(s): Natalie Taylor, PhD; Jonathan Searles

    Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.

    Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.

    Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.


    Related Reports

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details